Immunotherapy and radiotherapy for metastatic cancers.
Ann Palliat Med
; 8(3): 312-325, 2019 Jul.
Article
en En
| MEDLINE
| ID: mdl-30180743
ABSTRACT
Immune checkpoint inhibitors have emerged as a breakthrough therapy in the treatment in various metastatic cancers. In parallel, the role of radiotherapy in metastatic cancers has been expanding to include stereotactic ablative radiotherapy for oligometastases, in addition to the more conventional palliation of symptoms. Thus, many patients are appropriate candidates for both radiation and immunotherapy-highlighting the need for data to guide this treatment combination in patients with metastatic disease. Here, we review the literature to address questions regarding the safety of combined treatment (focusing on radionecrosis and pneumonitis), and the impact of dose, timing and site of radiotherapy. Finally, we highlight ongoing work investigating the potential local and systemic benefit to combining these therapies.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Cuidados Paliativos
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Ann Palliat Med
Año:
2019
Tipo del documento:
Article
País de afiliación:
Canadá